Why the study?
Does r-hirudin reduce hemorrhagic effects compared to heparin in patients undergoing cardiopulmonary bypass surgery?
Does r-hirudin reduce hemorrhagic effects compared to heparin in patients undergoing cardiopulmonary bypass surgery?
r-hirudin may offer a less hemorrhagic alternative to heparin for cardiopulmonary bypass, but the lack of a reversal agent remains a clinical challenge.
r-hirudin may lessen bleeding in bypass models; leaves open reversal needs and clinical validation.
Heparin is still the major anticoagulant of choice during CPB, but it may cause thrombocytopenia and severe bleeding in patients. In light of these complications, the devel opment of new anticoagulant drugs seemed to be necessary for these patients. Many experimental studies focused on r-hirudin, which presented a less hemorrhagic effect than heparin. How ever, neither antagonist has been shown to reverse this effect.
No takes yet. Share an insight, caveat, or question.
Belougne-Malfattie et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: